| Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer. | |
| | |
MedLine Citation:
|
PMID: 20093977 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: The best hope of cure for patients with non-small cell lung cancer (NSCLC) is surgical resection. However, even in stage IA patients, 30% die within 5 years. Further improvements in survival require a biomarker(s), which defines the subset of these patients destined to do badly so that they could be targeted for additional therapies. Here, we investigate whether the immunohistochemical expression of a key kinase implicated in lung cancer biology, the mammalian target of rapamycin (mTOR) can predict survival outcome in patients with early stage resected NSCLC. MATERIALS AND METHODS: One hundred thirty-four patients with resected early stage (IA-IIB) NSCLC were pathologically reviewed centrally before staining for mTOR. Multiple variables including age, sex, stage, angioinvasion, lymph node status, and mTOR staining were assessed by univariate and multivariate analyses. RESULTS: Stage (p = 0.044), lymph node status (p = 0.049), angioinvasion (p = 0.017), and mTOR staining (p = 0.007) were significant univariate predictors of poor survival. However, only angioinvasion (p = 0.016) and mTOR staining (p = 0.046) remained significant after multivariate analysis. Moreover, mTOR staining was the only variable to predict poor outcome in patients who either had negative lymph nodes (p = 0.016) or were stage IA (p = 0.0016). CONCLUSIONS: The mTOR staining provides a new biomarker for poor outcome in early stage NSCLC and could enable resected stage IA patients to be selected for novel therapies possibly with an mTOR inhibitor. |
| | |
Authors:
|
Tony Dhillon; Francesco A Mauri; Guido Bellezza; Lucio Cagini; Mattia Barbareschi; Bernard V North; Michael J Seckl |
Related Documents
:
|
11597807 - Computed tomography-guided frameless stereotactic radiotherapy for stage i non-small ce... 16262567 - Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung can... 18751427 - Erlotinib monotherapy in patients with advanced non-small cell lung cancer: an effectiv... 11948127 - Degradation of tenascin-c and activity of matrix metalloproteinase-2 are associated wit... 20582957 - Successful treatment of multiply relapsed lymphoma with rituximab as a single agent. 3141317 - Low-grade astrocytomas: treatment results and prognostic variables. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer Volume: 5 ISSN: 1556-1380 ISO Abbreviation: J Thorac Oncol Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-02-26 Completed Date: 2010-05-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101274235 Medline TA: J Thorac Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 314-9 Citation Subset: IM |
Affiliation:
|
CR-UK Laboratories, Imperial College London, Hammersmith Hospitals campus, London, United Kingdom. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenocarcinoma
/
metabolism,
mortality,
pathology Adenocarcinoma, Bronchiolo-Alveolar / metabolism, mortality, pathology Adult Aged Aged, 80 and over Carcinoma, Large Cell / metabolism, mortality, pathology Carcinoma, Neuroendocrine / metabolism, mortality, pathology Carcinoma, Non-Small-Cell Lung / metabolism, mortality*, pathology Carcinoma, Squamous Cell / metabolism, mortality, pathology Female Humans Immunoenzyme Techniques Intracellular Signaling Peptides and Proteins / metabolism* Lung Neoplasms / metabolism, mortality*, pathology Male Middle Aged Neoplasm Invasiveness Neoplasm Staging Prognosis Protein-Serine-Threonine Kinases / metabolism* Survival Rate Tissue Array Analysis |
| Grant Support | |
ID/Acronym/Agency:
|
//Cancer Research UK |
| Chemical | |
Reg. No./Substance:
|
0/Intracellular Signaling Peptides and Proteins; EC 2.7.1.-/mTOR protein; EC 2.7.11.1/Protein-Serine-Threonine Kinases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of recovery mode on exercise time to exhaustion, cardiorespiratory responses, and blood lacta...
Next Document: Biomechanical Testing of Two Devices for Internal Fixation of Fractured Ribs.